Current opportunities:

The following compounds are currently open for out licensing and/or co-development with a strategic partner:

HSV Pritelivir (AIC316)

Pritelivir - The perfect solution for resistant HSV infections at immunocompromised patients.

AIC649

AIC649 - Proprietary Immune Modulator and Potential Cure for Chronic Hepatitis B Infection